<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336908">
  <stage>Registered</stage>
  <submitdate>19/05/2011</submitdate>
  <approvaldate>10/08/2011</approvaldate>
  <actrnumber>ACTRN12611000841976</actrnumber>
  <trial_identification>
    <studytitle>The efficacy of low-power laser in amelioration of pain , dysesthesia and Lhermittes sign in multiple sclerosis patients</studytitle>
    <scientifictitle>The efficacy of low-power laser in addition to Gabapentin, compared to treatment with Gabapentin alone in the amelioration of pain and improvement of quality of life in multiple sclerosis patients</scientifictitle>
    <utrn>U1111-1121-2292</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple sclerosis</healthcondition>
    <healthcondition>pain</healthcondition>
    <healthcondition>Quality of life</healthcondition>
    <healthcondition>dysesthesia</healthcondition>
    <healthcondition>Lhermitte's sign</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Multiple sclerosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>different Probe that will be used on cervical and thoracic spinal culomn one after another:
1) MLO1K: Helium, Neon, Argon     Amplitude: 500-670 nm     Duration: 1-5 min     Power: 20 j/cm2     
2) KLO6: Helium, Neon     Amplitude: 500-670 nm     Duration: 10-40 second     Power: 172 j/cm2  
3) KLO3: Helium, Neon     Amplitude: 500-670 nm     Duration: 10-30 second     Power: 10/5 j/cm2
4) RED     Amplitude: 500-660 nm     Power: 10/9 j/cm2
 
Duration of laser therapy in each session: 10-15 min
Location: cervical and thoracic spinal cord
Frequency of sessions: once daily for 10 days(5 continuous days, 2 days rest, and another 5 continuous days)
 
Laser and Gabapentin capsule (300mg/day) will be administered simultaneously.</interventions>
    <comparator>Sham therapy for 10 session plus Gabapentin capsule(300mg/day) once daily for 10 days(5 continuous days, 2 days rest, and another 5 continuous days).
For the patients who should receive sham therapy, operator use the turned off laser probe</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Visual analogue scale score for pain.</outcome>
      <timepoint>Just after the last session and 2 weeks after that.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>SF-36 questionnaire for quality of life.</outcome>
      <timepoint>Just after last session and 2 weeks after that.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Definitive diagnosed MS with MC-donald 2010 criteria
Cervical pain, Lhermitte's sign, painful dysesthesia in upper limbs or pain in lumbar and pelvic regions and dysesthesia in shoulder girdle.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>MS attack or need for corticosteroid pulses.
Addiction or using drugs simultaneous with therapy.
Simultaneous using of regular powerful anti-inflammatory drugs
Other causes except than spinal cord plaques produce pain, dysesthesia and Lhermitte's sign.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomization will be done by person who is not involved in enrolling the patients and writes intervention group(A or B) in sealed opaque envelopes after determining its sequence. thereafter people who are undertaking enrolling, after checking the inclusion and exclusion criteria, open the envelope to determine the intervention group of each patient.</concealment>
    <sequence>Each group(laser/sham) are named A or B by someone who is not involved in enrolling, evaluation and analysis. According to randomization table, sequence of block will be defined. (Permuted block randomization)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/07/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tehran university of medical sciences</primarysponsorname>
    <primarysponsoraddress>Poor sina St, Enghelab Sq,
Tehran, 
Iran
postal/ZIP: 1417613151</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Tehran University of medical sciences</fundingname>
      <fundingaddress>Poor sina St, Enghelab Sq.
Tehran
Iran
postal/ZIP: 1417613151</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Masood Nabavi</sponsorname>
      <sponsoraddress>Mostafa Khomein hospital, Italia ST, 
Tehran, 
Iran

Postal/ZIP: 141665185</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Pain and sensory deficit is one of the main complaints of MS patients. Although there are some medical therapy for pain relief but they are associated with some side effects too; In the other hand low power laser is a secure and effective modality in relieving pain and dysesthesia from 2002 when FDA approve it.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethic committee of Tehran University of medical science</ethicname>
      <ethicaddress>poorsian St, Enghelab Sq, tahran, iran
postal/ZIP: 1417613151</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nabavi, seyed masoud</name>
      <address>Mostafa Khomeini Hospital
Vesal St., Italia St.
Tehran
Iran
Postal/ZIP 141665185</address>
      <phone>+982188963122</phone>
      <fax />
      <email>massood@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sadeghi Naini, Mohsen</name>
      <address>Num29, Karimi Alley, Arash Blv, Zafar St.
Tehran
Iran
Postal/ZIP: 1916649411</address>
      <phone>+989124934734</phone>
      <fax />
      <email>dr.msadeghi@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sadeghi Naini, Mohsen</name>
      <address>Num29, Karimi Alley, Arash Blv, Zafar St.
Tehran
Iran
Postal/ZIP: 1916649411</address>
      <phone>+989124934734</phone>
      <fax />
      <email>dr.msadeghi@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>